Review Article: PDF OnlyUse of Antimicrobial Peptides Against SARS-CoV-2 Today is the Future RetractedAlsabony, Mohamed N.1; Mehlotra, Rajeev K.2,3,*Editor(s): van der Veen, Stijn Author Information 1College of Sciences and Health Professions, School of Health Sciences, Cleveland State University, Cleveland, Ohio, USA 2Center for Global Health and Diseases, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA 3Department of Biological Sciences, Case Western Reserve University School of Dental Medicine, Cleveland, Ohio, USA. Corresponding author: Rajeev K. Mehlotra, Center for Global Health and Diseases, Case Western Reserve University School of Medicine, Biomedical Research Building, #409A, 2109 Adelbert Rd., Cleveland, OH 44106, USA. E-mail: [email protected]. How to cite this article: Alsabony MN, Mehlotra RK. Use of Antimicrobial Peptides Against SARS-CoV-2: Today is the Future Infect Microb Dis 2021;00(00):00–00. doi: 10.1097/IM9.0000000000000050 Received 12 November, 2020 Revised 11 December, 2020 Accepted 15 December, 2020 Funding: No funding was received for this work. Conflict of Interest: The authors reported no conflict of interest. This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 Infectious Microbes & Diseases: March 02, 2021 - Volume - Issue - doi: 10.1097/IM9.0000000000000050 Open PAP Metrics Abstract Antimicrobial peptides (AMPs), α- and β-defensins and cathelicidin LL-37, possess antiviral properties. These AMPs achieve viral inhibition through a diverse array of mechanisms. For example, they can bind directly to virions; they can bind to and modulate host cell-surface receptors, which disrupts intracellular signaling; and they can function as chemokines to augment and alter adaptive immune responses. Given their antiviral properties, and the fact that the development of an effective coronavirus disease 2019 (COVID-19) treatment is an urgent public health priority, they and their derivatives are being explored as potential therapies against COVID-19. These explorations are being carried out using a variety of strategies, ranging from their direct interaction with the virus to using them as vaccine adjuvants. So far, these strategies are showing promising results. However, AMPs do not work in isolation, specifically in their role as potent immune modulators, where they interact with toll-like receptors (TLRs) and chemokine receptors. Both of these receptors have been shown to play roles in COVID-19 pathogenesis. Therefore, including information on the interactions among all these players would produce a more complete picture of the response to AMP-based therapies. © 2022 by Lippincott Williams & Wilkins, Inc.